SCHEMBL10043751

SCHEMBL10043751

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3ccc(F)c(C(F)(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.53
KCNQ3 O43525 2/20 0.48
KCNQ2 O43526 2/20 0.48
KCNE1 P15382 1/20 0.48
KCNQ1 P51787 1/20 0.48
HTR2A P28223 1/20 0.47
TEK Q02763 1/20 0.46
BRAF P15056 6/20 0.44
THRB P10828 1/20 0.43
TNK2 Q07912 1/20 0.43
MAP4K2 Q12851 1/20 0.43
MAPK14 Q16539 3/20 0.43
MAOB P27338 2/20 0.43
LCK P06239 1/20 0.42
KDR P35968 1/20 0.42
JAK3 P52333 1/20 0.42
RAF1 P04049 2/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043661 0.94 SYK (0.55) SYKTEKBRAFTNK2MAP4K2
SCHEMBL10043758 0.91 LCK (0.53) SYKHTR2ABRAFTNK2MAP4K2
SCHEMBL10043845 0.91 SYK (0.45) SYKBRAFTHRBLCKKDR
SCHEMBL10043923 0.89 MAOB (0.53) SYKKCNQ3KCNQ2MAPK14MAOB
SCHEMBL10043663 0.86 SYK (0.51) SYKKCNQ3KCNQ2MAPK14MAOB
SCHEMBL10072021 0.86 SYK (0.59) SYKTEKBRAFMAPK14LCK
SCHEMBL10043750 0.86 SYK (0.49) SYKKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL10043705 0.86 MAPT (0.54) SYKMAPK14
SCHEMBL10043698 0.85 SYK (0.70) SYKTEKBRAFMAPK14LCK
SCHEMBL10043666 0.85 SYK (0.49) SYKKCNQ3KCNQ2BRAFMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KCNQ3 2453/4885KCNQ2 2398/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KCNQ3 2453/4885KCNQ2 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.